Mirum Pharmaceuticals (NASDAQ:MIRM) Receives "Overweight" Rating from Cantor Fitzgerald

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report)'s stock had its "overweight" rating restated by stock analysts at Cantor Fitzgerald in a research note issued to investors on Thursday, Benzinga reports. They currently have a $40.00 price objective on the stock. Cantor Fitzgerald's price objective points to a potential upside of 54.86% from the stock's previous close.

A number of other research firms also recently commented on MIRM. HC Wainwright reaffirmed a "buy" rating and set a $58.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday. JMP Securities lifted their price objective on shares of Mirum Pharmaceuticals from $69.00 to $72.00 and gave the stock an "outperform" rating in a report on Thursday, March 14th. SVB Leerink lowered their target price on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an "outperform" rating for the company in a research note on Monday, March 18th. Finally, Stifel Nicolaus began coverage on shares of Mirum Pharmaceuticals in a research report on Wednesday, April 17th. They issued a "buy" rating and a $48.00 price target on the stock. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $50.36.

Mirum Pharmaceuticals Stock Up 3.2 %

Shares of NASDAQ:MIRM traded up $0.79 during trading on Thursday, hitting $25.83. The company's stock had a trading volume of 631,760 shares, compared to its average volume of 544,566. The company has a market capitalization of $1.22 billion, a PE ratio of -6.51 and a beta of 1.13. Mirum Pharmaceuticals has a fifty-two week low of $23.14 and a fifty-two week high of $35.56. The company has a debt-to-equity ratio of 1.23, a quick ratio of 4.19 and a current ratio of 4.45. The stock's 50-day moving average price is $25.91 and its two-hundred day moving average price is $28.12.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.32). The business had revenue of $69.55 million for the quarter, compared to analysts' expectations of $66.73 million. Mirum Pharmaceuticals had a negative return on equity of 66.24% and a negative net margin of 86.33%. As a group, sell-side analysts expect that Mirum Pharmaceuticals will post -1.34 EPS for the current year.

Insider Activity at Mirum Pharmaceuticals

In other news, CFO Eric Bjerkholt bought 2,000 shares of the firm's stock in a transaction on Monday, March 18th. The stock was purchased at an average price of $25.80 per share, for a total transaction of $51,600.00. Following the transaction, the chief financial officer now owns 12,000 shares in the company, valued at $309,600. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt bought 2,000 shares of the business's stock in a transaction on Monday, March 18th. The shares were purchased at an average price of $25.80 per share, with a total value of $51,600.00. Following the purchase, the chief financial officer now directly owns 12,000 shares of the company's stock, valued at $309,600. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Peter Radovich sold 4,303 shares of the stock in a transaction on Monday, March 25th. The stock was sold at an average price of $25.80, for a total value of $111,017.40. Following the completion of the transaction, the chief operating officer now directly owns 29,013 shares of the company's stock, valued at approximately $748,535.40. The disclosure for this sale can be found here. 22.87% of the stock is currently owned by insiders.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. increased its stake in shares of Mirum Pharmaceuticals by 98.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 986 shares of the company's stock valued at $31,000 after acquiring an additional 488 shares during the period. AJOVista LLC bought a new position in Mirum Pharmaceuticals during the 4th quarter valued at $40,000. Wetzel Investment Advisors Inc. bought a new position in Mirum Pharmaceuticals during the 4th quarter valued at $41,000. StepStone Group LP acquired a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at $135,000. Finally, Quest Partners LLC bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter worth $194,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.